Amide Proton Transfer Radiotherapy for Brain Tumor

This trial tests a new MRI technique called amide proton transfer (APT) imaging to determine if it can better pinpoint aggressive areas in brain tumors for radiotherapy. The goal is to improve treatment accuracy and reduce side effects. Participants will receive either standard radiotherapy or the experimental APT-RT (Amide Proton Transfer Radiotherapy). Individuals diagnosed with glioblastoma or grade 4 astrocytoma who can undergo MRIs might be suitable candidates for this study. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could enhance future brain tumor treatments.

The trial information does not specify if you need to stop taking your current medications. However, you cannot be on any other investigational cancer treatment agents when you enroll.

Research has shown that amide proton transfer (APT) imaging is generally safe and well-tolerated by patients. APT imaging, a special type of MRI, helps doctors see brain tumors in detail. In past studies, patients experienced no significant side effects from APT imaging, indicating its safety in medical settings.

APT imaging has predicted certain features of brain tumors without harming patients. This technology allows doctors to understand and target tumors better without invasive procedures, potentially reducing the risk of unnecessary treatment side effects.

Amide proton transfer radiotherapy (APT-RT) is unique because it enhances the visualization of tumor infiltration in the brain, which might not be as clear with standard radiotherapy. This technique could potentially reduce the risk of radiation toxicity by targeting the tumor more precisely, sparing healthy tissue. Researchers are excited about APT-RT because it aims to balance effective tumor treatment with fewer side effects, offering a promising advancement in brain tumor care.

This trial will compare Amide Proton Transfer Radiotherapy (APT-RT) with standard radiotherapy (RT) for brain tumors. Research has shown that amide proton transfer (APT) imaging can identify the most aggressive parts of brain tumors. Studies have found that APT imaging distinguishes tumor tissue from other brain changes, such as swelling. This technique highlights areas with higher protein and peptide levels, often indicating increased tumor activity. In a study with 61 patients, APT imaging provided crucial information about brain tumors that guided treatment. It also enabled doctors to observe tumor responses to treatment earlier than usual methods.²⁴⁶⁷⁸